Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.

Protein science : a publication of the Protein Society - 1 Feb 2026

Abbinantefina Annalisa Pia, Tito Claudia, Masciarelli Silvia, Tisci Giada, Ceci Pierpaolo, Falvo Elisabetta, Ruta Veronica, Panzeri Valentina, Sette Claudio, Fazi Francesco, Colotti Gianni

Abstract excerpt

Activating KRAS mutations, particularly G12 variants, are key drivers in pancreatic ductal adenocarcinoma and other cancers. While KRAS was historically considered undruggable, mutant-specific inhibitors, including non-covalent KRAS G12D inhibitor MRTX1133, have emerged. However, efficacy and resistance remain challenges. We utilized a stimuli-sensitive, ferritin-derived nanomedicine platform to encapsulate high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Drug Carriers

Share to Ferritins

Share to Organoids

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 41556452
DOI: 10.1002/pro.70444
PMCID: PMC12817286

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.PMID 41556452Read ↗

Mutant KRAS is a druggable target for pancreatic cancer.Semantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer.Semantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.Semantic proximity Read ↗

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways.Semantic proximity Read ↗

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.